A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will be a double-blind, randomized, vehicle-controlled study with application of ruxolitinib phosphate cream or vehicle in patients with stable plaque psoriasis. Application will be QD for 12 weeks without occlusive dressings. There will be 4 treatments of 50 subjects each.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation

Criteria

Inclusion Criteria:

• Plaque psoriasis involving up to 2 to 20% Body Surface Area

Exclusion Criteria:

• Lesions solely involving intertriginious areas, the scalp or the face

• Systemic therapy for their psoriasis

• Pustular psoriasis or erythroderma

• Currently on other topical agents or UVB therapy within 2 weeks of the first dose of study medication

• Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis

• Receiving systemic triazole antifungals except fluconazole